Glass House BrandsGLASF -0.80%44 Days Payable is 92.11 as of Mar. 2026, which is 228% above its 10-year median of 28.06. GuruFocus rates GLASF with a GF Score™ of 44/100 and a GF Value™ of $6.15 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 923 Drug Manufacturers companies, Glass House Brands ranks worse than 75.19% on this metric.
The historical rank and industry rank for Glass House Brands's Days Payable or its related term are showing as below:
GLASF'
s Days Payable Range Over the Past 10 Years
Min: 25.09 Med: 28.06 Max: 49.99
Current: 49.99
During the past 6 years, Glass House Brands's highest Days Payable was 49.99. The lowest was 25.09. And the median was 28.06.
GLASF's Days Payable is ranked worse than 75.19% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs GLASF: 49.99
Glass House Brands's Days Payable
increased
from Mar. 2025 (30.09) to Mar. 2026 (92.11).
It may suggest that Glass House Brandsdelayed paying its suppliers.
Glass House Brands Days Payable Related Terms
Glass House Brands Days Payable Historical Data
* Premium members only.
The historical data trend for Glass House Brands's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Glass House Brands's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Glass House Brands Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Glass House Brands's Days Payable distribution charts can be found below:
* The bar in red indicates where Glass House Brands's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Glass House Brands's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Glass House Brands (GLASF) has a Days Payable of 92.11 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Glass House Brands and its competitors. This is 228% above median its historical median of 28.06. Over the past decade, Glass House Brands' Days Payable has ranged from 25.09 to 49.99. According to the industry distribution chart, Glass House Brands ranks #694 out of 923 companies in the Drug Manufacturers industry, placing it in the top 75.2%.
Is Glass House Brands' Days Payable too high?
Glass House Brands' current Days Payable of 92.11 is 228% above median its 10-year median of 28.06. Over the past 10 years, this metric has ranged from a low of 25.09 to a high of 49.99. The Drug Manufacturers industry median Days Payable is 90.98. Glass House Brands' value of 92.11 is 1.2% above this industry median. Based on the distribution chart, Glass House Brands ranks #694 out of 923 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Glass House Brands has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Glass House Brands' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Glass House Brands ranks #694 out of 923 companies for Days Payable. This places Glass House Brands in the lower half of its industry. The industry median Days Payable is 90.98. Glass House Brands' value of 92.11 is 1.2% above this benchmark. Historically, Glass House Brands' own Days Payable has ranged from 25.09 to 49.99 over the past decade. While the company's 10-year median is 28.06 vs. the industry median of 90.98, Glass House Brands has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Glass House Brands's current Days Payable of 92.11 is 1.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Glass House Brands and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Glass House Brands's current Days Payable is 92.11, which is 228% above median its own 10-year median of 28.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Glass House Brands stock overvalued right now?
Based on GuruFocus' analysis, Glass House Brands (GLASF) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.15, compared to a current price of $12.64 — trading 105.5% above its estimated fair value. The current Days Payable is 92.11, which is 228% above median its 10-year median of 28.06 and 1.2% above the Drug Manufacturers industry median of 90.98. Glass House Brands' overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Glass House Brands (GLASF), the current Days Payable is 92.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Glass House Brands (GLASF) Overvalued in 2026?
Based on GuruFocus' analysis, Glass House Brands stock appears to be overvalued.
The current stock price of $12.64 is trading 105.5% above its estimated GF Value™ of $6.15.
GuruFocus considers Glass House Brands to be Significantly Overvalued.
Key valuation signals for GLASF:
Days Payable: 92.11 (228% above median its 10-year median of 28.06)
GF Value™: $6.15 vs. price of $12.64 (105.5% above fair value)
Industry Position: 1.2% above the Drug Manufacturers median (#694 of 923)
No single metric tells the full story. See the GLASF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Glass House Brands Inc is an integrated cannabis company that operates exclusively in the state of California. Its portfolio of brands includes Glass House Farms, Forbidden Flowers, and Mama Sue Wellness. It cultivates, manufactures, and distributes cannabis bulk flower and trim to wholesalers and consumer packaged goods to third-party retail stores. It also owns and operates retail cannabis stores in the state of California. It has three reportable segments: Retail, Wholesale Biomass, and Cannabis-related consumer packaged goods. It generates the majority of its revenue from the Wholesale Biomass segment.
44GF Score
Get the complete analysis for GLASF
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GLASF has been successfully added to your 
